Roquin-dependent gene regulation in immune-mediated diseases and future therapies
International Immunology review by Temsse Raj, Arlinda Negraschus and Vigo Heissmeyer
04.04.2023
Raj T, Negraschus A, Heissmeyer V (2023 Apr 4) Roquin-dependent gene regulation in immune-mediated diseases and future therapies. Int Immunol. 35(4):159-170. doi: 10.1093/intimm/dxac059
Abstract cited directly from the review:
The RNA-binding proteins Roquin-1/2 and Regnase-1 exert essential regulation by controlling pro-inflammatory mRNA expression to prevent autoimmune disease. More recently, inhibition of this post-transcriptional gene regulatory program has been demonstrated to enable enhanced anti-tumor responses by tumor antigen-specific CD8+ T cells. In this review, we describe the functions of these RNA-binding proteins and the phenotypes that arise in association with genetic inhibition or inactivation. We discuss how inducible inactivation of the system reprograms CD4+ and CD8+ T cell fates by changing cell metabolism, activation, differentiation or effector/memory decisions. We furthermore outline what we need to know to precisely modulate this system in order to dampen autoimmune reactions or boost the efficacy of adoptively transferred T cells or chimeric antigen receptor (CAR) T cells in cancer immunotherapies.
